The inhibitory effect of PF06424439 on DGAT2 has been tested in preclinical models, and PF06424439 reduced LD formation and metastasis of gastric cancer in vitro and vivo (28). Several inhibitors of the mevalonate acid pathway have been tested in gastric cancer, and statin cholesterol-lowering drugs have been tested in clinical trials. The gene discussed is DGAT2; the disease is gastric cancer.